-
JC-1 Workflows for Mitochondrial Membrane Potential
2026-09-24
Use JC-1 to track mitochondrial polarization while testing how treatments affect cell stress and death. This practical guide links assay setup and troubleshooting to pulmonary fibrosis research, while clarifying what the dye can—and cannot—say about ferroptosis.
-
Murine RNase Inhibitor: Practical RNA Workflow Guide
2026-09-24
Protect RNA in RT-PCR, cDNA synthesis, transcription, and labeling workflows with an inhibitor designed for pancreatic-type RNases. Its oxidative stability is especially useful when a protocol calls for low DTT, while its specificity makes it important to match the inhibitor to the RNase activity you need to control.
-
Gut-Brain Cholinergic Signaling in Seizure Control
2026-09-23
Jia et al. identify a gut–vagus–brain cholinergic circuit through which Bacteroides fragilis suppresses seizures in mouse models and improves outcomes in a randomized trial of pediatric refractory epilepsy. The study connects microbial composition, colonic ChAT-positive cells, vagal transmission, and seizure regulation while highlighting important limits for translating animal mechanisms to patients.
-
JAK Inhibitors and Endothelial Vascular Effects
2026-09-22
This comparative endothelial-cell study shows that approved JAK inhibitors can suppress cytokine release without uniformly correcting adhesion, coagulation, or cell-survival abnormalities. Its concentration- and inhibitor-dependent results help separate anti-inflammatory activity from vascular safety signals in inflammatory disease research.
-
Dihydroartemisinin: Assay Workflows and Optimization
2026-09-22
A practical guide to using Dihydroartemisinin as a defined small molecule in mTOR, inflammatory, psoriasis, and parasite-focused experiments. The workflow separates early signaling changes from delayed loss of viability, helping researchers avoid overinterpreting a single endpoint.
-
JAK Inhibitors and Endothelial Cardiovascular Risk
2026-09-21
The reference study compares six JAK inhibitors in cytokine-stimulated human endothelial cells and shows that suppressing IL-6 does not uniformly normalize adhesion, coagulation, or cell-survival responses. Its concentration-aware design provides a useful framework for separating anti-inflammatory activity from vascular effects that may influence cardiovascular risk interpretation.
-
Bazedoxifene and IL-6/GP130 Cancer Signaling
2026-09-21
The 2024 review by Shi and colleagues examines Bazedoxifene, an established selective estrogen receptor modulator, as a repurposing candidate that can inhibit IL-6/GP130 signaling in cancer models. Its analysis connects computational target identification with preclinical evidence for pathway suppression, combination treatment, and further oncology investigation while emphasizing that clinical efficacy remains unestablished.
-
Tofacitinib Citrate: JAK3 Research Workflows
2026-09-20
Tofacitinib citrate enables concentration-aware studies of JAK-STAT signaling, lymphocyte biology, and inflammatory endothelial responses. This guide separates nanomolar immune-cell workflows from higher-concentration vascular stress models, helping researchers choose informative readouts and avoid overinterpreting cytokine suppression.
-
Zosuquidar: ABCB1 Resistance in PROTAC Assays
2026-09-19
Zosuquidar (LY335979) reveals how ABCB1-mediated transport can confound PROTAC efficacy measurements. This article translates recent resistance findings into practical assay-design guidance for multidrug resistance research and targeted protein degradation studies.
-
JNJ-26854165 (Serdemetan) Assay Guide
2026-09-19
A scenario-based guide to using JNJ-26854165 (Serdemetan), SKU A4204, in cell viability, proliferation, apoptosis, migration, and radiosensitization studies. It connects HDM2–p53 biology with practical decisions about endpoint selection, solubility, dose interpretation, and vendor reliability.
-
Rottlerin: A Causal Probe of PKC-Dependent Entry
2026-09-18
Rottlerin is a PKC inhibitor that connects kinase signaling with cancer phenotypes and virus entry biology. This guide explains how to interpret its selectivity, design time-resolved assays, and translate inhibitor results into defensible mechanistic conclusions.
-
Mitochondrial CAT-Tailing in Glioblastoma Growth
2026-09-17
The reference study identifies mitochondrial stress-induced carboxyl-terminal alanine and threonine tailing as a functional ribosome-associated quality-control response that supports glioblastoma survival, migration, and overgrowth. Its experiments connect CAT-tail-dependent remodeling of ATP synthase-associated mitochondrial behavior with membrane-potential maintenance and resistance to apoptosis, providing a mechanistic framework for studying mitochondrial stress in glioblastoma.
-
Lovastatin as a Translational Probe of Cell Fate
2026-09-17
Lovastatin is more than a cholesterol biosynthesis inhibitor: as an HMG-CoA reductase inhibitor, it provides a practical way to interrogate how mevalonate metabolism shapes proliferation, apoptosis, tissue remodeling, and macrophage clearance. This thought-leadership perspective connects those mammalian research applications with the systems-level logic of KNUCKLES-controlled floral meristem termination while clearly defining the evidence and translational limits of that cross-domain comparison.
-
EZ Cap EGFP mRNA 5-moUTP Workflow Guide
2026-09-17
Build more interpretable reporter experiments with a Cap1-capped, 5-moU-modified EGFP transcript designed for stable translation and reduced innate immune recognition. This guide connects cell-based expression assays with nanoparticle delivery, in vivo imaging, and practical troubleshooting.
-
Bazedoxifene Workflows for SERM Research
2026-09-16
Bazedoxifene supports tissue-selective estrogen receptor studies, bone mineral density enhancement models, and an emerging antimalarial repurposing workflow. This practical guide connects formulation, ER pathway assays, parasite-stage analysis, controls, and troubleshooting without conflating preclinical findings with clinical evidence.